INTRODUCTION on the 16th postconceptional week. Epithelial cells of bronchi
Statement of the problem. RDS' due to pulmonary surfactant deficiency (10) remains a major cause of perinatal mortality and morbidity despite progress in prevention and treatment (209) . An increased incidence of RDS in IDM was initially reported in 1959 by Gellis and Hsia (94) . Since that time, the influence of maternal diabetes on fetal lung development has become a field of intensive clinical and experimental animal research. These investigations have sometimes led to conflicting results and opinions. Whether or not maternal diabetes mellitus by itself has a direct effect on fetal lung maturity was the first controversial question to arise (80, 272) . Even if it is accepted that the diabetic state per se increases the incidence of RDS (at least in some defined classes of hyperglycemic mothers), the exact nature of the alterations in lung development and the mechanism(s) by which the metabolic disturbances impair the process of lung maturation remain poorly understood. In particular, the respective role of increased blood glucose and of fetal hyperinsulinism have not been clarified.
Clinical studies have usually been descriptive at best and have not provided cellular or molecular clues as to pathogenetic mechanisms. This is largely attributable to the limitations in clinical research since only observations on infants with lung disease and indirect studies using many different amniotic fluid tests have been possible. In basic research, a major limitation has resided in the problem of creating appropriate animal models that reproduce the characteristic features of human diabetic pregnancies. Thus, although clinical and basic information has led to improvements in both diagnosis and prevention, the abundance of sometimes contradictory data and the discrepancy between interpretations render the literature extremely confusing and call for an overall synthesis of experimental information dealing with both clinical and biological research. The purpose of this paper, therefore, is to review information from the literature and describe the different experimental approaches being used at present. Recommendations are made for improvements in and standardization of experimental design. Whenever possible, we present conclusions about what has been clearly established and what remains questionable. Additionally, we have proposed explicative hypotheses concerning implicated mechanisms.
Normal process of lung development. The human lung differentiates early in gestation from a ventral bud of primitive foregut epithelium and surrounding mesenchyme. A series of asymmetric branching gives rise to the bronchial tree which is completed ' Abbreviations: RDS, respiratory distress-syndrome; IDM, infants of diabetic mothers; PC, phosphatidylcholine; DSPC, disaturated phosphatidylcholine; PG, phosphatidylglycerol; L/S, lecithin/sphingomyelin; STZ, streptozotocin; PI, phosphatidylinositol: FFA, free fatty acids. and alveoli derive from the primitive-epithelium. During the saccular phase (from 25-26 wk until the postnatal period), the future alveoli are formed and the terminal epithelium differentiates into two principal cell types: 1) type I pneumocytes which form the thin wall of the alveolar sacs and facilitate gas exchange; 2) type I1 pneumocytes which during the last 10% of gestation show increased numbers of characteristic osmiophilic lamellar bodies, the intracellular storage form of lung surfactant. Simultaneous with appearance of lamellar bodies, the glycogen stores of these cells disappear.
When the lung is mature, pulmonary surfactant appears as a lipoprotein complex which facilitates efficient gas exchange by lowering surface tension at the alveolar-air interface (159) , and possibly by inducing water repellency in alveoli (1 33). Biochemically, the major components of surfactant are phospholipids. The principal constituent is PC, particularly DSPC, which is otherwise called disaturated lecithin (8 1) . Other phospholipids such as PG also are thought to play a functionally important role (81, 120) .
Increasing amounts of phospholipids are observed in lung tissue in association with accumulated lipid in type I1 pneumocytes. Similar changes in phospholipid concentrations are seen in tracheal and amniotic fluids as pregnancy progresses to term (8 1). On the basis of several studies in animals (reviewed in Ref. 8 l) , the elevated concentration of phospholipids has been attributed to increased de novo synthesis via the CDPcholine pathway. Biochemical changes underlying lung maturation are exceedingly complex, and although metabolic pathways for production of lipids such as PC have been identified, many important maturational processes and regulatory factors remain to be elucidated (8 1, 101, 104, 107, 122, 155, 204, 253) . Moreover the timing of key biological events in lung maturation varies among species.
To the extent that the results of Jobe et al. (148) in the rabbit fetus can be extended to the human species, it appears that newly synthesized PC reaches the alveolus after a long lag period, and alveolar stability would be entirely dependent during the early postnatal period upon phospholipids stored in anticipation of birth. Any impairment in phospholipid production in late gestation could, therefore, have prolonged consequences upon alveolar stability, even when an underlying maternal or intrauterine abnormality has ceased to be influential because of birth.
CLINICAL DATA
Heterogeneity of the diabetic pregnancy. Diabetes mellitus in pregnancy is not a unique pathological condition but rather a family of conditions whose common factor is glucose intolerance. Included among many variables are the time of appearance of glucose intolerance, variation of insulin requirements, and the severity of metabolic disturbances and of organ damage. Various classifications of diabetes mellitus exist. For the diabetic pregnancy, the system used widely is that of White (28 l), which takes
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namely gestational diabetes (class A), merits further description because it has been most frequently associated in the literature with delay of fetal lung development. It is characterized by abnormal glucose tolerance during pregnancy and reversal to normal pospartum. Its transient nature reflects the inability of the p cell to keep pace with the increased demands for insulin generated by the hormonal milieu of pregnancy associated with relative insulin resistance (4 1, 157) ; islet cell function is subsequently sufficient for glucoregulation in the nongravid state.
Lung developmental abnormalities associated with diabetic pregnancies. RDS may be defined as an acute restrictive pulmonary disease characterized by generalized atelectasis which develops shortly after birth in susceptible premature infants; this is principally due to pulmonary surfactant deficiency and often Ieads to progressive ventilatory failure (78) . The pathophysiology and epidemiology of the disease has been described in detail elsewhere (78) . In addition to prematurity, several other risk factors for RDS influence perinatal lung function including: 1) fetal sex [males more frequently develop fatal RDS (84, 188) ]; 2) mode of delivery [higher incidence of RDS after cesarean section delivery without antecedent labor (85, 272) l; 3) perinatal asphyxia and maternal hemorrhage [increased risk (801; 4) maternal diabetes with hyperglycemia [see below]; 5) maternal hypertension, intrauterine growth retardation, and prolonged rupture of membranes [(lower risk (19) l. Although humoral substances are potential mediators of these effects (13, 242) , the precise mechanism(s) remain unclear. Nevertheless, these factors provide clues as to how pulmonary surfactant synthesis may be regulated, particularly in utero.
In various clinical series the incidence of RDS in IDM has been as high as 37% (94, 139, 140, 279) . Usher et al. (272) pointed out that elective premature birth by cesarean section was the usual mode of delivery for IDM and that maternal diabetes was only one risk factor for these babies. Robert et al. (227) subsequently delineated the risk of RDS for diabetic offspring delivered in Boston from 1958 to 1968. According to these authors, who compared 805 IDM to 10,152 infants of nondiabetic mothers, the uncorrected risk for RDS among IDM was 23.7 times those of infants born to mothers without diabetes mellitus. Even when corrected for gestational age, maternal age, type of labor, route of delivery, birth weight, sex, Apgar score, hydramnios, prepartum hemorrhage, and maternal anemia, the risk remained 5.6 times as great in IDM as in the control population. More recent statistical studies are confirmatory (4) . It should be recalled that increased susceptibility to respiratory distress is only one of numerous clinical problems encountered with IDM, other disorders include macrosomia and its consequences on parturition, neonatal hypoglycemia, and congenital malformations (42, 137, 180) .
Although the risk of lung immaturity leading to RDS at birth appears to vary in the different classes of diabetes, discrepancies exist among reported studies, probably because of the fact that not only RDS but a variety of biochemical and biophysical indices of lung maturity was used as endpoints. There is general agreement that inadequately controlled class A (gestational) diabetes can increase the risk of RDS or at least cause delayed fetal lung maturation as judged by phospholipid determinations or by biophysical measurements on amniotic fluid samples (88, 103, 110, 152, 161, 185, 237) .
The situation is more complicated with classes B and C diabetes which have been considered to delay, to not affect, or to even accelerate lung maturation. Gluck and Kulovich (103) using the lecithin/sphingomyelin (L/S) ratio in amniotic fluid, Singh et al. (27) using the degree ofsaturation of amniotic fluid lecithin, Cruz et al. (43) considering L/S ratio and incidence of RDS, Goldkrand and Slattery (I 10) using globule formation from the amniotic fluid lipid extract, and Higuchi et al. (132) measuring surfactant lipoprotein concentration in amniotic fluid all concluded that delayed fetal lung maturation occurred in pregnancies with classes B and C diabetes. Delayed evolution of rising L/S ratios and occurrence of RDS with classes B and C diabetic pregnancies have also been reported by Mueller-Heubach et al. (190) . On the other hand, Curet et al. (48) found no evidence of delayed maturation in carefully regulated diabetic pregnancies as estimated by amniotic fluid L/S data, and Kulovich and Gluck (161) reported even higher L/S ratios in fetuses of classes B and C diabetes than in age matched controls. Also, Farrell et al. (83) found no evidence for delayed lung maturation based on determination of saturated lecithin in amniotic fluid; also this group found no increased incidence of RDS in IDM. Signs of accelerated lung maturation have been reported in some chronically stressed pregnancies of classes B and C with accompanying hypertension, preeclampsia, or premature rupture of membranes (284) . Nevertheless, one can conclude that classes B and C diabetes in pregnancy can delay fetal lung maturation in some instances, even if some biochemical data are discrepant. The discrepancies probably are due to clinical variables such as the succeis of hySrglycemia management (i.e. insulin therapy) and the demee of chronic intrauterine stress. as well as to the indirect and imprecise nature of endpoints studied.
For diabetes classes D, E, F, and R, conflicting results have also been reported. In these instances, accelerated rather than delayed fetal lung maturation was reported by most ofthe authors who studied L/S ratio or phosphatidylglycerol in amniotic fluid (36, 100, 103, 16 1, 186,240) . This acceleration was contested by Curet et al. (48) on the basis of L/S ratio determinations.
Additionally, Lowensohn and Gabbe (168) found a similar incidence of RDS in classes B through R and in nondiabetic pregnancies when the L/S ratio was considered as mature, which would argue for an absence of differences between these classes and normal pregnancies with respect to fetal lung maturation.
Available data suggest that the worse the control of maternal blood glucose, the higher the risk of RDS and other morbidities (1 52). This also argues for the direct role of the maternal metabolic disturbances upon fetal lung development. Consequently, the incidence of RDS in diabetic pregnancies appears to be decreasing with improvements in maternal care during pregnancy (48, 83, 92) . Nevertheless, RDS continues to occur (with significantly greater frequency) in pregnancies with gestational diabetes (88) . Because this class of diabetes appears to be most associated with delayed fetal lung maturation, it is possible that these patients may not be as carefully managed as those known to be diabetic prior to pregnancy. Thus, their diabetic state could possibly be less well controlled or disclosed too late in pregnancy for optimal treatment. This risk of RDS also might be slightly higher in infants of prediabetic mothers whose diabetes develops later in life (4) . These observations indicate the importance of screening for glucose intolerance during pregnancy.
In conclusion, a potentially increased risk of RDS due to delayed fetal pulmonary maturation appears associated with recent diabetic conditions without severe complications, i.e. class A and sometimes classes B and C, whereas longstanding, more complicated diabetic states, especially with accompanying vascular disease (i.e. classes D through R or classes B and C with stress), appear more often associated with accelerated maturation. It may be inferred, therefore, that maternal hyperglycemia per se, that is to say with elevated blood glucose as the sole pathological feature, can cause a delay in fetal pulmonary functional maturation. On the other hand, when diabetes is longstanding and/or when severe complications occur either before (vascular disease of classes E, F, and R) or during (classes B, C, and D) pregnancy, chronic intrauterine stress occurs whose effects can potentially counteract those of maternal hyperglycemia and lead to accelerated fetal lung maturation. This is in keeping with data from studies of animals indicating that stress hormones stimulate lung maturation (242) .
Antenatal predic!ion of RDS in diabetic pregnancies by amnioticfluid analysis.
Because of the lack of direct access to human fetal lung, amniotic fluid has been used extensively to assess lung maturation and to schedule elective deliveries to minimize the
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risk of neonatal respiratory disease. Although this approach allows only an indirect and crude reflection of what is actually happening within the developing fetal lung, its reliability is generally well established (270) . Various methods for measuring amniotic fluid surfactant have been reviewed recently (89, 202, 270) . The L/S ratio in amniotic fluid has been widely accepted for 15 yr as a valid test for pulmonary maturity (105, 106) and is now supplemented with other determinations such as measurement of PG (1 18-120,211) , PI (121, 122) , and DSPC (83)-all of which show characteristic changes during late gestation.
The reliability of the L/S ratio in diabetic pregnancies has been a source of controversy. A lower amniotic fluid L/S ratio in late gestation as cumpared to normal pregnancies of the same duration was mentioned by several investigators, especially in early studies (103, 127, 190, 216, 217, 237) . More recently, others observed no significant difference (48, 83, 91, 123, 161, 22 1). Among the possible causes of these conflicting results are the large variations of L/S ratio in normal as well as in abnormal pregnancies, and technical factors which vary from study to study such as acetone precipitation (106), centrifugation (203) , the use of one or two dimensional chromatography (47), and the method of phospholipid quantitation (202) . Also, the degree of diabetic control may be an important factor affecting L/S ratio, which would explain why early observations reported differences which are no longer evident in more recent series with better control (48, 83). Therefore, whether maternal diabetes actually impairs the rise of amniotic fluid lecithin, remains an unsolved question. Moreover, a higher incidence of false-positive predictions of fetal lung maturity using L/S ratio has been reported for diabetic pregnancies (43, 49, 64, 79, 186, 190, 237) , although a few investigators considered the test as reliable as in normal pregnancies (6 1, 9 1, 1 68, 263) .
Diabetes mellitus in pregnancy has been shown to cause a marked reduction, or even an absence, of PG in amniotic fluid when compared with age-matched nondiabetic pregnancies (45, 46, 1 16 , 1 17, 123, 124, 241, 268) . According to Kulovich and Gluck (161) (123) , when RDS occurred with a L/S ratio over 2, PG was absent.
TOWARD THE UNDERSTANDING OF MECHANISMS, THE EXPERIMENTAL APPROACHES
Need for animal models. Understanding the mechanism(s) of impaired fetal lung biochemical development associated with maternal diabetes mellitus probably cannot be achieved solely with the aid of clinical data for several related reasons: 1) direct access to the lung is possible only postmortem, which allows study of only fatal cases in which secondary alterations are certain to be present; 2) generally only collection and analysis of amniotic fluid, or at the most of bronchopulmonary fluid at birth, is possible in humans; 3) it is impossible to control completely the important clinical variables in human pregnancies (e.g. changing care practices make the diabetic pregnancy of this era much different than 10-20 yr ago).
Use of animal models is necessary for control of the involved metabolic factors and a systematic analysis of their mode of action. Thus there is a crucial need to design animal models reproducing features of the fetal environment in the diabetic pregnancy. This would make it possible to determine conclusively if fetal lung surfactant is developmentally abnormal and, if so, what metabolic factors account for the disturbances associated with maternal diabetes.
Maternal hyperglycemia appears to be the precipitating cause of most the characteristic features of the fetus of diabetic mother (206) . The most prominent feature of the "milieu interieur" of fetuses of diabetic mothers is the unique association between hyperglycemia and hyperinsulinemia. It seems reasonable to presume that these factors are primarily involved in the process leading to the potential delay of fetal lung maturation.
Hyperglycemia due to increased placental transfer of glucose has long been recognized in the fetus of the diabetic pregnant woman, and was proposed in the early years of relevant research to induce a hyperinsulinemic fetal state (63, 205) . Direct demonstration of hyperinsulinemia in infants born to insulin-treated mothers has been difficult because of the interference in the radioimmunoassay for insulin caused by placentally transferred endogenous insulin antibodies (146) . Because of this analytical problem, only indirect evidence of the fetal hyperinsulinemic state was available at first, including: 1) / 3 cell hyperplasia and increased pancreatic insulin in fetuses of diabetic pregnancies (254) , and 2) an increased rate of circulating glucose disappearance in newborn infants of diabetic mothers (1 45). More recently, direct demonstration of hypersecretion of insulin by the fetal pancreas in diabetic pregnancies has been obtained by measurement of cord blood C-peptide levels (250) . Placental transfer of maternal insulin (endogenous or exogenous) is not involved in the increase of fetal blood insulin levels since insulin does not cross the human placenta (150). A primate animal model of maternal-fetal glucose relationships was used by Chez et al. (37) to show a rapid increase of fetal blood glucose and insulin, with a linear relationship between maternal and fetal plasma glucose, within minutes following maternal glucose loading (injection plus infusion). The insulin response of the fetal pancreas after the 12th wk of human gestation is thought to be induced by the increased blood glucose stimulating the @ cell; this is reinforced by the ingestion of glucose from the amniotic fluid and its insulinogenic action on the fetal digestive tract (1 34).
To investigate the effects of high fetal serum glucose and/or insulin concentrations on fetal lung maturation, investigators have used both in vitro and in vivo approaches. In vitro experiments have been based on the property of lung cells, either in organ culture or in cell culture, to pursue their differentiation and maturation in relatively simple systems. These studies were initiated before in vivo experimentation of this problem with the observation by Smith et al. (243) that insulin inhibits the stimulatory effect of cortisol on DSPC synthesis in rabbit fetal lung cell cultures. In vitro studies subsequently focused attention on hyperinsulinemia as the major factor delaying fetal lung development. It was proposed (9, 259) that the increased insulin levels in the fetus of the diabetic pregnant woman retard the normal glucocorticoid-regulated stimulation of lung maturation. In vivo studies have included animal models of induced diabetes in pregnancy. They have led, on the contrary, to the conclusion that increased blood glucose is the main factor for the delay of lung maturation. The results of in vitro and in vivo studies need to be reviewed in detail for one to understand the basis of these conclusions.
Before examining fetal lung studies, it is useful to review the consequences of diabetes mellitus upon adult lung in order to help one better understand what makes fetal lung development in the diabetic pregnancy a special problem.
Experimental insulin deprivation in adult animals treated with STZ or alloxan results in lung abnormalities whose final consequence is a reduction of lung surfactant phospholipid production (188, 189, 283) . Although the degree of lung lipid alterations varies, Engle et al. (70) recently found that decreases in DSPC concentration correlated with the severity of hyperglycemia. The reduction in pulmonary phospholipid levels is probably related to a decreased capacity of de novo fatty acid synthesis (32,33,52) and incorporation into PC. Surfactant phospholipids are also decreased in lung lavage fluid (260) . Insulin was found by Sharp et al. (234) to directly stimulate PC synthesis in granular epithelial lung cells. The effects of insulin could be mediated, at least in part, through thyroid hormone action since chemically induced diabetes reduces nuclear triiodothyroine binding capacity of rat lung nuclei, according to Das and Ganguly (51). In the adult lung, therefore, insulin appears to be a regulatory factor necessary for normal surfactant synthesis. On the contrary, an excess of insulin, as in the fetus of the diabetic pregnancy, may have an adverse consequence on surfactant production, as reviewed subsequently.
Insulin and fetal lung development-in vitro studies. Monolayer cultures prepared from fetal rabbit lungs of 28 days gestation (mixed population of lung cells) were first reported as insulin responsive in 1975 (243) . Earlier, corticosteroids, whose stimulating effects on fetal lung maturation are well established (160, 164, 165) , were shown to increase 3H-choline incorporation into PC (244, 245) . Although, insulin alone had a slight positive effect on choline incorporation, insulin added to cultures with cortisol significantly reduced the corticosteroid-stimulated PC synthesis (243) .
In another isolated cell system used by Engle et al. (69) , i.e. organotypic cultures of fetal rat type I1 pneumocytes, the presence of low concentrations of insulin (10-25 pU/ml) caused an increase in the incorporation of glucose into surfactant PC, but higher levels (100, 250, or 400 pU/ml) significantly decreased incorporation of both glucose and choline. Elevating the media glucose concentration from 5.6 to 20 mM caused a 2-to 2.5-fold increase in glucose utilization for phospholipid synthesis, but did not produce any changes in choline incorporation and thus apparently did not alter de novo synthesis of PC as assessed with an isolated surfactant fraction. On the other hand, addition of 400 pU/ml of insulin to media containing 20 mM glucose did result in significantly lowered choline incorporation into surfactant PC. These data suggest that insulin is an important hormone regulating fetal lung phospholipid metabolism, that its effects are dose (concentration) dependent, and that high levels of insulin predominate over glucose in causing an inhibition of surfactant formation.
Exposure of fetal rat lung explants to insulin for 24 h by Gross et al. (1 12) resulted in a significant increase in the glycogen content and the rate of glucose oxidation to COz (1 12) . No effect of insulin was observed on the rate of labeled choline incorporation into PC or DSPC, which conflicts with the results of Smith et al. (243) . Insulin did reduce significantly the incorporation of acetate into DSPC, but increased the incorporation of acetate into general membrane phospholipids, namely phosphatidylethanolamine, phosphatidylinositol, phosphatidylserine, and sphingomyelin. This argues for a specific inhibiting action on the synthesis of DSPC which reflects surfactant phospholipid. One of the most interesting observations of that study was the delay of morphological maturation of the lung cells induced by insulin: the number of type I1 cells and lamellar bodies was significantly decreased in insulin-treated explants as compared with control explants cultivated without insulin. As a whole, this study suggests that insulin stimulates cellular growth and inhibits cellular differentiation and maturation of the fetal lung in vitro. In another study, insulin was shown to prevent in part the dexamethasone-induced stimulation of choline phosphate cytidylyltransferase in cultured fetal rat lung explants (230) . This suggests that the apparent antagonism of insulin on corticosteroid-induced stimulation of fetal lung PC synthesis may be at least partly expressed at the level of this key enzyme of the CDPcholine pathway.
Bourbon et al. (29) recently reported a direct precursor-product relationship between fetal lung glycogen and phospholipids, a relationship that had long been postulated on the basis of morphological and biochemical observations (2 1, 3 1, 99, 159, 17 1). In this in vitro study, glycogen, which accumulates before the surge of surfactant production, appeared from their data to be used preferentially as a precursor for DSPC and PG, the phospholipids most characteristic of surfactant, while free glucose served as a precursor of many lipids including membrane phopholipids. Insulin both reduced DSPC and PG synthesis and decreased the transfer of radioactivity from previously in vivo labeled glycogen to DSPC and PG. Although a high glucose concentration in the medium had the same effects in the absence of insulin the effects of insulin and glucose were additive.
Other data on in vitro insulin effects have come from experiments with lung slices incubated directly (without culture) in the presence of labeled precursors. Neufeld et a/. (199) studied the effects of insulin on the incorporation of labeled glucose and fatty acid residues into total PC and DSPC in lung slices of rabbit fetuses. When labeled glucose was used, the incorporation into PC and DSPC was reduced by insulin despite an increase in overall glucose utilization by lung tissue. Insulin also decreased labeled palmitate incorporation into DSPC. Considered together, these in vitro studies suggest that insulin is capable of impairing fetal lung maturation both structurally and biochemically. This appears contrary to the situation in the adult lung in which insulin seems to favor the biosynthesis of surfactant phospholipids; however, the evidence for a dose-response relationship identified in fetal lung cells (69) must be kept in mind as the probable explanation for this apparent discrep ancy. Nevertheless, the following criticisms suggest caution in the extrapolation of in vitro results to the clinical situation and indicate that more experimental data are needed.
1) The insulin concentrations used in the culture media generally range from 10 to 1000 pU/ml and are probably not representative of those in the lung environment in vivo.
2) In studies reporting measurement of the rate of incorporation of radiolabeled precursors added to the medium, there is uncertainty as to the exact significance of the observed rate of net surfactant PC or DSPC synthesis. In most studies, except for that of Engle et al. (69) , total pulmonary PC or DSPC rather than that in surfactant PC or DSPC was measured.
3) Studies to date report measurement of radiochemical rather than biochemical rates because the pool sizes of the various precursors inside the cells and in the various subcellular compartments are not known. Tokmakjian and coworkers (265, 266) showed that because of the marked decrease in the pool size of cholinephosphate during development (demonstrated at least for the rat and rabbit fetus), a change in the incorporation of radioactive choline into PC may not be indicative of a change in PC production by the de novo biosynthetic pathway.
4) Incorporation of a precursor into a substance in vitro can be observed without net accumulation of this substance because of turnover processes with equal synthesis and degradation. This has been observed for instance in liver cells that incorporate labeled glucose into glycogen proportional to time with no change in glycogen concentration in the tissue (J. Bourbon, unpublished data). Thus an insulin-induced decrease of precursor incorporation into lung phospholipids does not definitely demonstrate that insulin affected the net synthesis of these phospholipids to the same magnitude. The ultrastructural observation of Gross et al. (1 12 ) that insulin decreased the number of lamellar bodies in fetal lung explants and the observation of Bourbon et al. (29) that insulin reduced the accretion of tissue DSPC during the culture period provide more convincing evidence.
5) Regarding the significance of the insulin-cortisol antagonism in isolated fetal lung cells by Smith et al. (243) , it should be reiterated that Gross et al. (1 12) failed to observe this antagonism. Also, considering that antgonism as an explanation of the mode of action of insulin in vivo presupposes that endogenous corticosteroids effectively control fetal lung maturation. This point is controversial since studies in fetal lambs (14, 178) and monkeys (208) clearly showed that surfactant-related phospholipids appear in increased amounts before the rise in fetal corticosteroid levels. The same could also be true for the human fetus (35). Additionally, there seems to be little correlation between the level of amniotic fluid cortisol and the degree of fetal lung maturation in human neonates (22 l), although the late increase of amniotic fluid palmitratelstearate ratio seems to correlate with the level of conjugated corticosteroids (194) . One can wonder if the postulated insulin-cortisol antagonism is not of a pharmacological nature.
Animal models of diabetes for in vivo study of fetal lung development. Animal models for human diabetes mellitus, their appropriateness, and their availability have recently been reviewed extensively by an NIH Task Force (230) . In brief, these models can be classified into two main categories: 1) animal strains with spontaneously occumng, genetically induced diabetes; 2) animals (rodents, dogs, or monkeys) with chemically induced diabetes due to infusion of pancreatic &cell toxic agents such as alloxan or streptozotocin (STZ). In addition to these widely used models, studies on fetal development also have used nondiabetic animals chronically infused with glucose when pregnant, fetuses with reactional hyperinsulinism, and fetuses chronically infused with insulin.
The intrauterine injection of long-acting insulin into rat fetuses has been shown to reproduce some of the features of IDM, i.e. increased length and body weight, increased organ weight, higher fat, and nitrogen content (6, 213) . In the fetal rhesus monkey, chronic fetal hyperinsulinemia achieved with aid of subcutaneously implanted, osmotically driven minipumps confirmed that several characteristics of IDM such as fetal overgrowth may be attributed to fetal hyperinsulinism (l75,26 1). The same group (3) and Rooney et al. (229) failed to observe any effect of chronic hyperinsulinemia u on morphological development and phospholipid content o f fetal lung, but the time of gestation (141 + 2 days and 134-148 days, respectively) chosen to study lung tissue was too early. Warburton et al. (277) using the same experimental approach in fetal lambs from 112 to 135 days of gestation observed a markedly decreased flux (about 26 times less) of surface active material into the tracheal fluid of insulininfused fetuses as compared to controls. This finding is supported by the recent report of diminished L/S ratio values in amniotic fluid of rabbit fetuses rendered hyperinsulinemic by litter reduction in utero (163) . Thus, chronic hyperinsulinism without accompanying hyperglycemia delays the secretion of surface active material by fetal lung. When secondary hyperinsulinemia was induced by chronic glucose infusion to fetal lambs, it inhibited the maturational response of fetal lungs to cortisol (276a).
There is little information regarding fetal development in genetically diabetic animals. Large for gestational age newborns have been observed in some pregnancies in the BB/W rat (166) but nothing is known about lung function at birth in these strains. On the contrary, animals with drug-induced glucose intolerance have been widely used to investigate the influence of the diabetic pregnancy state upon fetal lung development. It is unclear, however, which of the animal models of chemically induced diabetes reviewed below will prove most useful in elucidating the mechanisms of delayed fetal lung maturation. Ideally, an experimental model of diabetes in pregnancy would have to reproduce the characteristic features of the human fetus of the diabetic mother: hyperglycemia, hyperinsulinemia, and macrosomia. Hyperglycemia should not be extreme since this is unlikely to be encountered routinely in human pregnancies. Pitkin and Van Orden (25) observed that in STZ-treated pregnant rats, fetal hyperinsulinemia was present only when glycosuria was minimal. Such a model appears closer to human diabetic pregnancies than models with very marked glycosuria and no fetal hyperinsulinism. If fetal hyperinsulinemia is not present, the model is not a proper model of human diabetes but rather a model of chronically increased fetal blood glucose, with probable severe toxicity for the @ cell which does not appear able to respond to glucose over-load. As for macrosomia, it should be noted that IDM may in fact be either oversized, small for dates, or normal, i.e. appropriate in size for gestational age. Oversized infants are usually observed in those forms of maternal diabetes associated with delayed lung maturation, i.e. in patients with hyperglycemia appearing during pregnancy (gestational diabetes) but without severe com~lications, whereas small for date infants are observed in those diabetic conditions with vascular disease (54) in which acceleration of lung maturation often occurs. Fetal hypertrophy has been directly correlated with fetal hyperinsulinism in humans (250) , as well as experimentally in rhesus monkeys (3, 26 1) . A model of diabetes most suitable for the study of lung development retardation would, therefore, include macrosomia of the fetus.
In fact, the rodent models used commonly for studies of lung development have generally failed to reproduce the features described above. Maternal hyperglycemia has frequently been quite pronounced (up to 35 mmol/liter or 640 mg/dl), while fetal hyperinsulinemia and macrosomia have generally been absent. The relevance of the animals to clinical situations is therefore questionable. However, models devoid of fetal hyperinsulinism present the potential advantage of dissociating the putative effects of high glucose and high insulin.
Another point of controversy is the time for administration of the P-cell toxic agent. Since STZ crosses the rhesus monkey placenta (234) and can alter the fetal rat pancreas (17), a direct effect of the drug on fetal organs is possible, independently of maternal metabolic disorders, when the drug is given to already pregnant animals. It was recommended by the NIH Task Force to infuse the toxic agent before mating (82) . Nevertheless, it must be mentioned that STZ has not been associated with fetal lung toxicity thus far. In those studies in which animals were rendered diabetic prior to mating or immediately after mating, the consequences upon fetal lung development were similar to those in studies with drug injection during the course of pregnancy. Both types of experiments can therefore be compared.
The first studies of fetal lungs were performed using rhesus monkeys (term = 165 days) injected with STZ when 40-75 days pregnant. Gluck et al. (102) found elevated amniotic fluid L/S ratios in diabetic macaque pregnancies compared to matched controls. Epstein and Farre11 (73) and Epstein et al. (74) reported no change in lung PC concentration but an increase in I4C-choline incorporation into PC in lung slices prepared from fetuses of STZ-treated mothers as compared to control fetuses at 140-146 days gestation despite the presence of fetal macrosomia and P-cell hyperplasia. More recently, Kemnitz et al. (153) studied lung development in a small number of 145day-old rhesus fetuses whose mothers were infused with STZ before mating. Observations on lung biochemistry and physiology have been inconclusive thus far. However, fetal lung glycogen concentrations were 28% higher in diabetic animals compared to normoglycemic controls. These results in monkeys are difficult to interpret. The stage for lung study was not ideal since the major changes occur between 145 and 165 days (208) . Further investigation will be necessary to delineate the possible abnormalities in the process of fetal lung maturation in this model.
In rats (term = 22 days), inducing maternal diabetes at midgestation with STZ led to increased glycogen, DNA, and lipid contents of the lungs of neonates, no change in PC content, but a decrease in the percentage of DSPC (225) . The neonatal body weights were reduced in the litters of diabetic rats. Serum glucose was increased 3-fold in the STZ-treated mothers at delivery, but no information was given regarding fetal blood glucose and insulin in this study.
In fetuses of rats made diabetic with STZ on day five of gestation, Boutwell and Goldman (30) observed significantly decreased labeled choline incorporation into PC in lung slices, as compared with control fetuses on day 20 of gestation. Moreover, the in vivo uptake of 'H-dexamethasone by lung nuclei was significantly diminished in fetuses of STZ-treated mothers. This suggests the possibility of a decreased fetal pulmonary receptivity for corticosteroids in experimental diabetes. Tyden et a[. (27 1) also used the STZ-diabetic rat, with mating being performed 2 to 4 wk after induction of hyperglycemia. Morphologically, the fetal lungs at day 20 of gestation were less developed in the STZ group compared to controls with more abundant mesenchyme, less completely developed alveolar ducts, and less welldifferentiated pulmonary epithelium. Labeled choline incorporation by fetal lung slices was decreased in the diabetic group compared to controls; insulin treatment of the mothers abolished this dimi- decrease of PG content in the lung of fetuses in manifest STZdiabetic rat pregnancies at term; additionally, they found a concomitant 60% rise in PI content. In the model used for these three studies, maternal blood glucose levels were at least three times the normal value and fetuses were consistently small for gestational age; however, fetal blood insulin was below the normal level (214). The impairment of PG biosynthesis therefore appears as a direct consequence of raised blood glucose. The possible molecular mechanisms are considered subsequently.
BOURBON
Grant ef a[. (1 10) reported on a profound remodeling of lung basement membrane during type I1 cell development, with basal cytoplasmic foot processes extending through discontinuities of the basement membrane. The number of these foot processes was diminished in fetuses of diabetic rats (1 11) but the significance of these changes is thus far unclear. Models of diabetes in the rabbit (term = 3 1 days) have led to similar observations as in rats. Bose ef al. (26) induced diabetes in pregnant rabbits with alloxan, and studied lungs of fetuses that were hyperglycemic but had neither hyperinsulinemia nor macrosomia. On day 28 of gestation, fetal pulmonary maturity was assessed by measurement of pressure-volume relationships to determine deflation stability. Interpretation of the data is based on the fact that mature fetal lungs with adequate surfactant retain more air on deflation than immature ones, reflecting greater alveolar stability. Fetuses of diabetic rabbits demonstrated less retention of air on deflation than control fetuses of the same gestational age, but it has been suggested recently that the results of pressure-volume measurements in immature lungs are questionable because of the trapping of air by liquid which alters the air spaces on deflation (23 1). Additionally, levels of DSPC were diminished in the fluid obtained from lavage of the lungs in fetuses of diabetic mothers.
The rabbit with alloxan-induced diabetes was also the model used by Sosenko ef al. (247,25 1, 252) with the drug injected 24 h after mating. Pressure-volume curves at 27.5 days demonstrated less deflation stability in the fetuses of diabetic pregnancies compared to controls, but the difference was no longer observed on day 29. 5 (25 1,252) . The surface activity of lung lavage liquid measured on a surface balance was less in fetuses of diabetic mothers at both 27.5 and 29.5 days of gestation, despite the observation that DSPC and L/S ratio in lung wash and DSPC in lung tissue were not significantly different in fetuses of diabetic mothers. The reason for this discordance is unclear. From a morphological point of view (247), the lungs of the fetuses of hyperglycemic mothers appeared less mature than control lungs with a decrease of air space density and a higher glycogen content of type I1 cells. However, the proportion of type I1 cells and the number of lamellar bodies per type I1 cell were similar in control and in alloxan fetuses.
Ultrastructural examination of capillaries demonstrated (247) that their migration and the fusion of their basement membrane with that of alveolar epithelium did not occur as frequently in fetuses of alloxan-treated does as in controls. This observation is of considerable potential significance since it implies the possibility of lesser substrate supply to the type I1 cells in the alloxan fetuses at the time of intense synthesis of surfactant material. In this model, no differences were observed in the incorporation of labeled choline into PC and DSPC in lung slices of fetuses from diabetic mothers in comparison to control fetuses (56,25 1). The authors concluded that the previously observed functional abnormalities were not due to a defect of DSPC synthesis, which is consistent with the results of lung wash analyses. However, besides being in contradiction with other studies in rats and rabbits (26, 30, 225, 27 l), this result does not imply that in vivo incorporation of choline occurred at the same rate as in vifro. Placing the tissue in vitro in a metabolic and hormonal environment (Krebs-Ringer solution free of glucose and insulin) markedly different from that in vivo could have modified its metabolic behavior. It should also be noted that in these studies with alloxan diabetic rabbits, the animals were severely hyperglycemic throughout gestation, the fetuses were small for gestational age, and there were no measurements of blood insulin levels. MacFadyen (176) also studied phospholipids in the lungs of fetuses from alloxan diabetic rabbit pregnancies accompanied by reduced fetal body weight; the L/S ratio was lower than in controls, but phospholipid content was similar.
Sosenko ef al. (248, 249) reversed the functional delay of lung maturation in fetuses of diabetic rabbits with cortisol. This does not imply that alloxan diabetes acts through an impairment of endogenous cortisol effects, but it could have clinical consequences as to the potential usefulness of corticosteroid treatment to prevent lung immaturity in diabetic pregnancies. In two studies with rabbit models, the fetuses exhibited not only hyperglycemia but also hyperinsulinemia. One was reported by Memt ef al. (177) with rabbits rendered diabetic prior to gestation with STZ. Fetal weight on day 29 was normal, and the fetuses were only slightly hyperglycemic. Lung phosphatidylinosit01 metabolism was altered, but the significance for lung functional maturation is unclear since decreased phosphatidylinositol content has been proposed to signify an accelerated lung maturation. On the other hand, the observed increase of plasma myoinositol appears unfavorable to fetal lung maturation since in normal development the decrease of the percentage of phosphatidylinositol in surfactant has been correlated with a gestational decline in plasma myoinositol concentration (25). It is regrettable not to have information about DSPC and PG in this interesting model of diabetes.
Neufeld ef al. (196, 198) also obtained hyperinsulinemic fe-tuses with pregnant rabbits made diabetic with alloxan on day 14 of pregnancy. The lung concentrations of sphingomyelin, phosphatidylcholine (total and disaturated), and phosphatidylserine were significantly lower in fetuses of diabetic rabbits than in controls. For PG, the difference was not significant which contrasts with most of the clinical data concerning human diabetic pregnancies (based on amniotic fluid analyses). Treatment of the diabetic rabbits with 3,5-dimethyl 3'-isopropyl-L-thyronine, a thyroid hormone analogue, restored the phospholipids of fetal lung to normal (198) . Changes in fetal lung receptivity to insulin are also possibly involved, although contradictory data have been reported. An increased number of apparent receptors has been observed by some (196) in the lungs of fetuses from diabetic rabbits, as previously observed for mcnocytes and erythrocytes in humans (1 97,207) , whereas others found this number diminished in fetal lungs from rat diabetic pregnancies (193) .
In conclusion, the fetal lungs in animals with induced diabetes showed some characteristics consistent with a delay of maturation including less deflation stability, reduced incorporation of precursors into PC and PG, immature cellular or ultrastructural aspects of lung parenchyma, delay in glycogenolysis, and sometimes decreased DSPC and/or PG content of lung tissue or lung fluid. Despite the criticisms which can be made about the significance of some of these measurements, all the studies suggest that some impairment of lung maturation occurred in these models. Since increased blood insulin in the fetus was often not observed in these induced diabetic pregnancies, one must conclude that fetal hyperglycemia alone can delay lung maturation.
Hyperglycemia versus hyperinsulinemia.
From the above reported experiments, either excessive blood glucose or excessive insulin alone appear sufficient to cause a delay of fetal lung maturation. The question, therefore, arises as to which of them is effectively responsible for the impairment in lung development encountered in some human diabetic pregnancies.
It is clear that the adverse effects of excessive insulin upon lung development have been deduced mainly by in vitro experiments, often with greater than physiological concentrations of insulin. However, Engle et al. (69) demonstrated inhibition of surfactant phospholipid synthesis by organotypic cultures of fetal lung cells in the presence of 100-400 jd.J/ml, a level of insulinemia found in fetuses of diabetic pregnancies (153) . On the other hand, the experimental animal models of diabetes suggest that fetal hyperinsulinism need not accompany hyperglycemia to cause a delayed lung maturation in vivo. It is therefore tempting to ascribe the important role to hyperglycemia. In most of the models of induced diabetes, however, maternal blood glucose was quite high (up to 35 mmol/liter or 640 mg/dl). The deleterious effects of hyperglycemia on fetal lung maturation could be less in humans who are not likely to reach such levels. Additionally, in those models of the diabetic pregnancy with fetal hyperinsulinemia (1 77, 198, 239) , abnormalities in fetal lung development were observed in the presence of rather moderate hyperglycemia. The putative implication of fetal hyperinsulinism is still supported by two additional kinds of indirect evidence. First, in a clinical study, Draisey et al. (62) found a reverse correlation between insulin concentration and lecithin concentration and degree of saturation in human amniotic fluid beyond 35 wk of gestation. Also, Beck et a[. (20) observed a dramatic increase in maternal and fetal plasma insulin values when the pregnant rhesus monkey was treated with betamethasone. Contrary to previous reports in other species (55, 160, 164, 187) the corticosteroid in this model failed to stimulate the fetal lung surfactant system. The authors suggested that the betamethasone-induced hyperinsulinemia could have impaired the acceleration of surfactant production by the steroid. Further research is needed on this interesting proposal.
For the time being it does not seem possible to reach a judgment as to the relative importance of hyperglycemia and hyperinsulinemia. It is likely that both are implicated in human diabetic pregnancies, and that they act either synergistically or on different but additive mechanisms.
THE POSSIBLE BIOCHEMICAL MECHANISMS
General considerations. Unquestionably, both clinical and biological approaches indicate that the etiology of fetal lung developmental retardation due to diabetes in pregnancy relates in some way to altered pulmonary surfactant metabolism. Whatever the cause, hyperglycemia or hyperinsulinemia, the diabetic pregnancy must lead to biochemical disturbances in the developing lung which translate into a delayed functional maturation. Both the major surface active constituents of surfactant, DSPC and PG, appear to be present in inadequate amounts at birth. Although the pathogenetic mechanisms at the molecular level leading to this situation are not yet elucidated, available experimental data allow us to propose several hypotheses. Figure 1 summarizes the putative mechanisms of abnormal fetal lung development due to the metabolic changes in diabetic pregnancies. The impairment may be either direct, i.e. at the levels of DSPC and PG biosynthetic pathway and/or secretion, or indirect, i.e. being the consequence of an inadequate substrate availability or utilization for surfactant synthesis.
Direct impairment of surfactant biosynthesis and/or secretion by insulin or glucose.
Nothing is known about the activity of phospholipid biosynthetic pathways in the lung of human fetuses of diabetic mothers. In animals with induced diabetes, decreased enzyme activities have been observed in fetal lung only when the mother was severely diabetic (200, 253) , a condition in which the fetuses are generally not hyperinsulinemic. Indications of a possible adverse effect of excessive insulin upon lung phospholipid biosynthesis have been gained exclusively from in vitro experiments. Insulin was shown to prevent the corticosteroidinduced increase of choline phosphate cytidylyltransferase activ- 
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BOURBON AND FARRELL ity in fetal rat lung explants (230) . However, decreased incorporation of choline into PC in vitro was not caused by insulin alone (1 12, 243) . On the contrary, a decreased incorporation into DSPC (but not into membrane phospholipids) induced by insulin was observed for glucose, acetate, and palmitate (1 12, 199) .
The effect of insulin on palmitate incorporation into PC suggests that one defect could take place at the level of the phosphatidylcholine-lysophosphatidylcholine remodeling mechanism described in Figure 2 . The observations of Ishidate and Weinhold (144) strongly suggest that synthesis of disaturated PC from unsaturated PC and the disaturated species of diacylglycerol is a major route for the synthesis of surfactant dipalmitoylphosphatidylcholine via PC remodeling in fetal lung, and that diacylglycerols would represent obligatory donors of saturated fatty acids (mainly palmitate) in the transacylation remodeling pathway. Additionally the pool of 1,2-diacyl-sn-glycerol increases 5-fold during the fetal and neonatal periods in the rat (265, 266) . However, it must be kept in mind that the acyltransferase activities were not decreased in the lung of hyperinsulinemic rat fetuses of the mildly diabetic rat (238) . On the other hand, insulin is known to stimulate the uptake of FFA from fetal blood (2 13a) and their incorporation into adipose tissue triglycerides (6, 2 13) . It therefore appears possible that high fetal blood insulin levels in the diabetic pregnancy could favor the incorporation of FFA into a fetal lung pool of triglycerides, but in opposing lipolysis, could decrease the availability of diglycerides for PC transacylation. As for hyperglycemia, it is unlikely to interfere with this process since glucose stimulated the incorporation of I4C-palmitate into PC in isolated perfused adult lung (1 8) .
In regard to the molecular mechanisms of insulin action, several propositions can be formulated at present. There is some evidence that the adrenergic system could participate in the control of surfactant biosynthesis (53, 179) and pulmonary maturation (2, 72, 15 l), and that this control is mediated by cyclic AMP (16, 17, 1 14,233) . P-Adrenergic receptors are present early in fetal lung (97, 282) and increase near term (282) .
Not only biosynthesis but also secretion of surfactant could be defective in IDM as suggested by the observation of a decreased release of surface active material in the chronically hyperinsulinemic sheep fetus (295). Many observations suggest that surfactant release into alveoli is under P-adrenergic control. P-Sympathicomimetic agents stimulate surfactant release from fetal lung in vivo (2, 23, 67, 71, 72, 128) , as well as from adult rat alveolar type I1 cells in vitro (60) . Epinephrine infusion to the sheep fetus also increases surfactant efflux (1 62). Labor promotes surfactant secretion from fetal rabbit lung, probably mediated through P receptor stimulation since P blocking agents abolish this effect of labor (174) . Finally, a recent study (58) established a significant positive correlation between human amniotic fluid levels of catecholamines and the L/S ratio, thus corroborating the results of animal experiments.
In other tissues such as liver or muscle, the antagonist effect of insulin versus the stimulation of adenylate cyclase by catecholamines or glucagon is well established. In the lung it appears possible that insulin could impair the maturational process as well as surfactant secretion by opposing cyclic AMP synthesis. An alternative mechanism would involve a disturbance in prostaglandin metabolism in the fetus of diabetic mother, as discussed subsequently.
Insulin could still inhibit the production of fibroblast-pneumocyte-factor (36a), a factor produced by lung fibroblasts, which stimulates pneumocyte maturation and whose production is corticosteroid responsive (24 1 a) .
Another possible explanation at the molecular level involves an effect of excessive amounts of myoinositol upon PG synthesis. It has been reported that fetal lung biochemical maturation is accompanied by a change from the production of a phosphatidylinositol (PI)-rich surfactant to one rich in PG (1 2 1, 122) . The reciprocal changes in the relative proportions of PI and PG in broncho-alveolar surfactant suggest a regulation at the level of a common precursor of both these lipids, most likely CDPdiacylglycerol (see Fig. 2 ). This intermediary substrate is present in minute amounts in mammalian cells (280) . There is evidence on one hand that limited availability of CDPdiacylglycerol may restrict the biosynthesis of PG and PI and, on the other hand, that a competition exists between the pathways of PG and PI biosynthesis for the amount of CDPdiacylglycerol available (66, 77, 90, 115 ). An increase in the extracellular concentration of myoinositol in experiments with various tissues studied in vitro (including lung) was followed by an enhancement of PI biosynthesis at the expense of PG biosynthesis (66, 77, 115) . The availability of myoinositol therefore appears to be a potential regulatory factor for surfactant composition in the developing lung (1 15) . This is consistent with the observation that the plasma concentration of myoinositol is much higher in the fetus than in the adult and falls dramatically toward the end of gestation in rats (34) and rabbits (25). The activity of pulmonary myoinositol-1 phosphate synthase (cyclase) also is elevated in the rabbit fetus as compared to the adult and decreases near the end of gestation,
i.e. between days 25 and 28 (25).
An increase of fetal plasma myoinositol level has been reported in two experimental rabbit models of the diabetic pregnancy, both of which were accompanied by fetal hyperglycemia and hyperinsulinemia. One was STZ-induced diabetes (177); the other involved continuous glucose infusion to the pregnant rabbit between days 27 and 29 (125) . On the contrary, chronic hypoglycemia in the pregnant rabbit and its fetuses by continuous insulin infusion to the doe was accompanied by a decrease of fetal serum myoinositol concentration and a concomitant stimulation of surfactant phospholipid production (particularly PG) by fetal lung (125) . Moreover, glucose was shown to stimulate myoinositol uptake by lung slices in vitro, an active transport system (25). Fetal hyperglycemia and/or hyperinsulinemia therefore appear able to increase myoinositol availability, uptake, and utilization by the developing lung. The absence, or delay in appearance, of PG in fetal lung surfactant reported in human diabetic pregnancies may therefore be the consequence of the presence of excessive amounts of myoinositol in fetal blood at the time when it normally declines.
A last hypothesis that can be formulated for molecular mechanisms concerns a possible deleterious effect of protein glycosylation by excessive glucose. One type of glycosylated proteins is Hb A,, whose level is abnormally high in diabetic subjects (222) . Whether or not the presence of glycosylated proteins influences fetal lung maturation is unknown but cannot be excluded. Proteins other than Hb can presumably be glycosylated in the presence of high blood glucose concentrations, including enzymes or hormone receptors and their biological activity could potentially be modified. Such events may intervene in the lung of the developing fetus of the diabetic mother and affect functional maturation.
Alterations in utilization ofprecursor pools. In comparing fetal to adult lung from a biochemical point of view, one major difference is the presence in the former of high amounts of reserve substances, such as glycogen (mainly in epithelial cells) and mono-, di-, and triglycerides in lipofibroblasts. Although the potential importance of this may not be immediately apparent, it must be kept in mind that the lung only receives about 10% of the cardiac output in utero, whereas the adult lung is perfused with virtually the entire cardiac output and thus is continuously presented with an abundant supply of substrates and nutrients. The fetal lung stores may therefore compensate for lower blood flow. In addition to the low proportion of the cardiac output perfusing fetal lung, the necessity of glycogen utilization for the synthesis of phospholipids of surfactant is perhaps linked to the environment of epithelial cells in developing lung. As shown in the rat fetus, the majority of type I1 epithelial cells have no contact until birth with capillary endothelial cells, from which they are separated by mesenchymal cells, namely the lipofibroblasts (1 73) . This is probably the cause of the rather low exchange between blood and fetal lung epithelium and a possible reason for the apparent necessity to use previously stored precursors for the intense synthesis of phospholipids just prior to birth in short gestational species. If these substrate stores are indeed necessary for the normal process of surfactant phospholipid elaboration, the effect of maternal diabetes could be exerted through inhibition of the mobilization of stored molecules when they are needed to support augmented phospholipid biosynthesis. It is well known of course that both hyperglycemia and hyperinsulinemia inhibit glycogenolysis and lipolysis. In fact, glycogen stores rather than glycerides may be primarily concerned since glycogen in lung epithelial cells begins involution and utilization in utero (154, 171, 235) , whereas the utilization of glycerides stored in lipofibroblasts appears to take place shortly after birth (39, 273).
It should be emphasized that an impairment of glycogen breakdown in fetal lung was a constant finding in models of induced diabetes. Also obvious is the fact that insulin or high glucose concentration impaired glycogenolysis (29, 1 12) and glycogen utilization for synthesis of the phospholipids of surfactant in fetal rat lung tissue studied in vitro (29) . The increased blood glucose might therefore stimulate lung glycogen accumulation but prevent glycogenolysis as it does in fetal rat liver (98) .
Bourbon and Jost (27) showed that the surge of corticosteroids of fetal origin appears tb be the primary signal controlling fetal lung glycogen breakdown. This confirmed previous assumptions of Blackburn et al. (24) and Gilden et al. (99) . In fact, the effect of corticosteroids could be indirect. It has been shown that aminophylline, an inhibitor of phosphodiesterase which enhances cellular cyclic AMP levels, and cyclic AMP itself, stimulate both glycogenolysis and the synthesis of phospholipids in fetal rat or rabbit lung in vivo and in vitro (17, 172, 200, 233) . Corticosteroids have been shown to inhibit phosphodiesterase activity and to increase cyclic AMP concentration in rabbit fetal lung (1 7), and to increase the number of P-adrenergic receptors in rat fetal lung explants in vitro (170) . In addition, it is well established that corticosteroids are partly responsible for the maturation of the fetal adrenal medulla (228) . Epinephrine increases during late gestation in fetal blood of sheep (149) and rats (22) and in human amniotic fluid (59, 212) . For fetal lung, the cascade of events could therefore be: 1) surge of fetal corticosteroids: 2) maturation of fetal adrenal medulla and secretion of epinephrine into fetal blood in increasing amounts; 3) enhancement of cyclic AMP production in fetal lung; and finally 4) glycogenolysis. Cyclic AMP would be responsible not only for phosphorylase activation, according to its usual mode of action, but also would lead to glycogen synthase inactivation (27, 172, 178) and enhancement of autophagic activity (27). The importance of autophagic hydrolysis of glycogen for surfactant synthesis is also suggested by the existence of numerous lysosomal structures in fetal lung epithelium (12) and by the fact that lamellar bodies in type I1 pneumocytes are related to lysosomal structures and possess acid hydrolases (57, 109, 136) .
Sodoyez-Goffaux et al. (246) observed a high concentration of insulin receptors in rat lung at the pseudoglandular stage (day 17 of gestation) but a much lower concentration later (days 19 and 21). They speculated that insulin receptors may modulate lung glycogen metabolism, their presence favoring accumulation of glycogen during the pseudoglandular stage, whereas their partial disappearance would later allow glycogen breakdown and surfactant synthesis. The same is true in the rabbit fetus in which the maximzl insulin receptor number of lung tissue was observed on day 29 of gestation with an abrupt fall the day after (56a), although glycogen breakdown in rabbit fetal lung is already detectable on day 28 of gestation (27). Taking into account the increase of blood insulin and the subsequent prevention of decay of lung insulin receptors in the fetus of diabetic mother, this would explain the delay of lung glycogenolysis.
Bourbon et al. (28) reported a much more impaired glycogen utilization in the lung of fetuses of mildly diabetic rats than in the lung of fetuses of severely diabetic rats despite the fact that DSPC biosynthesis was impaired to the same extent in both cases. Since enzyme activities of phospholipid biosynthesis are decreased in severe but not in mild diabetes (253) , it appears that the mechanisms leading to delayed lung maturation could be different according to the severity of diabetes. Impaired glycogen utilization seems directly related to fetal hyperinsulinemia and is present in mild but not in severe diabetes. This suggests that this mechanism could be predominant in the human fetus of diabetic mothers with reactional hyperinsulinemia.
Alterations in the intermediary metabolism of glucose also have been suggested by Stubbs and Stubbs (259) who proposed that stimulation of pyruvate dehydrogenase by hyperinsulinism in the lung of the fetus of the diabetic mother may increase the conversion of glucose into lactate and acetyl-CoA, thus decreasing the availability of glycerol-3-phosphate for phospholipid synthesis. This assumption has not received demonstration but is supported by the following observations. The rate of lipid production in the lung could be partially regulated by the availability of two intermediates of glycolysis, glycerol-3-phosphate, and dihydroxyacetone phosphate (see Fig. 2 ). If insulin increases lactate production in the fetal lung as in the adult lung (258) , this means that hyperinsulinemia in the fetus of diabetic mother may stimulate the glycolytic pathway increasing lactate production, and thus decreasing the accumulation of glycerol-3-phosphate for lipid synthesis.
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The impairment of biosynthesis of surfactant phospholipids could still be an indirect consequence of altered lipid metabolism, particularly lipogenesis. It has been shown that both adult rat lung (224, 264) and fetal rabbit lung (126) take up FFA from blood and incorporate them into neutral lipids and phospholipids. The availability of FFA could potentially influence pulmonary maturation, since alterations in maternal dietary fat affect the concentration of saturated PC in fetal rat lung tissue (1 87) . However, recent investigations in rats (147, 169) suggest that in late fetal life de novo fatty acid synthesis is the major source of saturated fatty acids for phospholipid biosynthesis in fetal lung, and that exogenous palmitate inhibits de novo FFA synthesis. Any increase of fetal blood FFA, which might at first glance appear favorable for fatty acid incorporation into newly synthesized phospholipids, could in fact inhibit the necessary de novo fatty acid synthesis in type I1 pneumocytes and finally lead to decreased DSPC and PG production.
In insulin-dependent diabetics, plasma FFA and triglycerides often are elevated. If this is reflected in fetal plasma in the diabetic pregnancy, it could conceivably affect fetal lung phospholipid metabolism. Although fatty acids can cross the placenta readily from mother to fetus in most species [including rat (141) , rabbit (68, 274) , guinea pig (129), sheep (275) , monkey (218) , and man (50,262)], the quantitative importance of this placental transfer is not clear (201) . In the pregnant rat, the work of Koren and Shafrir (158) indicated that the transfer of palmitate, stearate, and linoleate is very small and that the maternal circulation cannot be an important source for direct transfer of FFA. In other species, such as rabbit and guinea pig, a much greater proportion of FFA seems to be transfered from mother to fetus (65, 129) . The case of the human placenta is unclear. Measurement of plasma fatty acids in human cord blood suggest that there is limited transfer of FFA throughout the last trimester of pregnancy ( 1 35).
The situation is complicated by the fact that not only maternal plasma FFA but also plasma triglycerides (as very low-density lipoproteins) seem to be a source of fetal fatty acids, at least in the rat (142) . Recent examination of triglyceride levels in cord blood of human newborns (38) however, seems to indicate that it is independent of the maternal serum triglyceride concentration. In the pregnant diabetic rat, on the contrary, placental transfer of triglycerides and/or FFA is clearly increased (233a) .
The consequence of the elevation of plasma lipids in the pregnant diabetic upon fetal lipidemia is therefore an unsolved question. Systematic examination of lipid levels in cord blood and cord arteriovenous differences at birth could perhaps help to answer this question.
Circulating glycerol is also a precursor for pulmonary PC in the developing mammalian lung (182) . The concentration of blood glycerol is increased in diabetic states (167) and also seems elevated in umbilical venous blood of IDM (2 10). Although this situation would appear rather favorable for phospholipid synthesis, Scholz et al. (232) have shown that glucose decreased the apparent utilization of glycerol by the isolated-perfused adult rat lung, suggesting that glucose and glycerol share a common metabolic pool in rat lung. In the presence of hyperglycemia, the use of circulating glycerol for phospholipid synthesis could therefore be reduced despite its higher availability. Additionally, because the common metabolite in the metabolic fate of glucose and glycerol is glycerol-3-phosphate, the use of circulating glycerol could also be affected at this level by the previously described possibility of pyruvate dehydrogenase stimulation in the presence of high insulin.
Endocrine or humoral abnormalities. The probable implication of the / 3 adrenergic system (mediated by cyclic AMP) in lung biochemical maturation and surfactant release also allows one to propose another possible cause of impaired fetal lung development in the diabetic pregnancy, namely altered fetal (and neonatal) sympathoadrenal status. Any impairment of epinephrine secretion or of norepinephrine activity in the fetus would have consequences upon surfactant biosynthesis and/or secretion. Conflicting reports have been published in the literature as to the level of sympathoadrenal activity in IDM. Blood catecholamines have been reported to be elevated at birth by some observers (8, 13 1, 285) , while others observed reduced catecholamine secretion in the first days of life (1 30,255) . Metanephrine, a metabolite of epinephrine, is present in lower amounts in amniotic fluid in some diabetic pregnancies (7). Artal el al. (7, 8) proposed a synthesis of these findings, namely that there would be a decreased sympathoadrenal activity or a delayed maturation of the system in fetuses of diabetic mothers, while at birth these infants would react excessivelv to the stress of labor and delivery, thus secreting excessive amoints of catecholamines; this would temporarily deplete them of catecholamines in the
It is difficult to reach a judgment about the possible consequences of this situation upon lung surfactant synthesis and release. Lower sympathoadrenal activity during pregnancy could be unfavorable to lung maturation through several mechanisms (activation of enzyme activities for surfactant biosynthesis, availability of diacylglycerol, glycogen breakdown and utilization, etc.). High levels of catecholamines at birth would appear rather favorable for surfactant secretion. Catecholamine depletion, however, could thereafter cause an inadequate surfactant secretion in the next several hours after birth. On the other hand, reabsorption of lung liquid, which is controlled in part by increased fetal epinephrine secretion in the perinatal period (276), would be enhanced by high catecholamine levels at birth. This appears contradictory to reports of transient tachypnea of the newborn in IDM and with Strang's (256) proposal of impaired lung liquid reabsorption at birth in the etiology of respiratory distress. These aspects of lung physiology in IDM remain to be clarified by further clinical and physiological investigations.
Many other hormones including corticosteroids, estrogens, prolactin, and thyroxin are able to stimulate fetal lung maturation (242) , although the exact role of endogenous hormones is still unclear. Low plasma concentrations of estrogens, prolactin, and thyroid hormones have been reported in infants with RDS (40,44 108, 138) as compared with age-matched controls, which suggests that fetal lung immaturity could be attributable to an insufficient action of stimulating hormones.
Unfortunately, the potential role of maternal diabetes in fetal hormone abnormalities is unknown, since in the pertinent clinical studies either there were no indications about maternal diabetes in the cases studied or maternal diabetes was a criterion for exclusion and the differences compared to controls were clearer after exclusion of IDM. Very little is known about the hormonal status of IDM for hormones other than insulin, glucagon, and catecholamines. Aarskog (1) found no difference in cortisol production rate between IDM and newborns of normal mothers. Cortisol levels in amniotic fluid increase normally in diabetic pregnancies (22 1). Measurement of adrenal and thyroid gland weights at autopsy revealed no difference between IDM and controls but pituitary weight was slightly reduced in IDM (143) . However, in fetuses of experimentally diabetic rabbits, plasma cortisol was lower than in normal fetuses (1 13). Corticosterone was similarly diminished in fetuses of STZ diabetic rats (192) . Further documentation on this point appears necessary.
In one case report (5), RDS occurred in an IDM in the presence of a mature amniotic fluid phospholipid profile, including the presence of phosphatidylglycerol.~hisbaby also had congenital hvvothvroidism and suvvlemental thvroxine led to normalization. he re~resentativik of that case.-however. is auestionable.
~e c e n t l~, -a n involvekent of pros~glandin'meiabolism has been implicated in the delay of lung maturation associated with the diabetic pregnancy. prostaglandins are known to regulate cyclic AMP levels in many tissues and the lung is an active organ of arachidonic acid metabolism for prostaglandin synthesis (1 83).
It is therefore possible that cyclic AMP levels in fetal lung and their developmental consequences were modulated by prostaglandin production in fetal lung. This assumption is reinforced by the existence of a high capacity for prostaglandin E2 biosynthesis beginning around 23 days of gestation and peaking at 28 days in fetal rabbit lung (219), i.e. at the very time of fetal lung biochemical maturation. Moreover, prostaglandins seem to be involved in the increased flux of surfactant occumng in late gestation ( 156) .
The observation of an altered vascular arachindonic acid metabolism in IDM (257) raises a question about maternal diabetes impairing lung maturation, at least partly, through altered fetal lung production of prostaglandins. Tsai et al. (269) assessed arachidonic acid metabolism in lung homogenates of fetuses from alloxan diabetic rabbits. They observed a decreased conversion of arachidonic acid to prostaglandin E2 as compared with control fetuses, whereas all other metabolites were produced in similar quantities. The authors suggested that the decreased production of prostaglandin E2 could be partially responsible for the functional delay of lung maturation in offspring of alloxan diabetic rabbit. However, it must be pointed out that the degree of difference from controls, although significant, was small and that the consequence of this reduction upon cyclic AMP biosynthesis are unknown. It does not seem likely that this reduced prostaglandin E2 production may account for the totality of the features which characterize the delay of fetal lung maturation observed in diabetic rabbits.
SUMMARY AND FINAL PERSPECTIVE
It seems quite likely that the normal process of fetal lung biochemical maturation is delayed by maternal diabetes and that abnormalities in the pulmonary surfactant system are involved. The appearance of PG in amniotic fluid and possibly in fetal lung is impaired or at least delayed. The same is possibly true for DSPC, the main constituent of surfactant, but recent discrepant data call for further clarification of this specific point.
Careful determination of the fetal lung phospholipid profile by amniotic fluid analysis helps predict and prevent RDS in IDM, along with a careful control of the maternal diabetic condition. A study of alveolar surfactant at birth, if it could be performed in addition to amniotic fluid analysis, would help to better characterize surfactant deficiency in IDM.
On the basis of both in vivo and in vitro experimental approaches, it seems clear that hyperglycemia and fetal reactional hyperinsulinism are both involved in the processes delaying fetal lung maturation. Further advances in the understanding of cellular and molecular mechanisms leading to this delay will be conditional on the availability of animal models reproducing the features of the metabolic and hormonal environment of human fetuses in diabetic pregnancies. The appropriateness of in vivo models needs to be defined by two kinds of criteria: 1) presence of simultaneous hyperglycemia and hyperinsulinemia in the fetus; 2) the presence of delayed fetal lung maturation as judged by morphology and morphometry of epithelial lung cells, by physiological assessment of surfactant, and by the phospholipid composition of the lung (and including lung tissue per se, bronchoalveolar lavage fluid, lamellar bodies, and/or isolated surfactant fractions). Therefore, future studies must necessarily be comprehensive in scope and include information indicating that fetal growth, blood glucose, and circulating insulin are all increased.
Such models already exist in rats and rabbits. Rat models are possibly not the best because of the high basal level of fetal blood insulin in this species and the relatively rapid rate of lung maturation that is not analogous to the human. Monkey models are of interest, because of their close relationship with the human pregnancy, and need to be studied further. They are particularly attractive also because primary fetal hyperinsulinism can be studied (268) , as well as the combination of hyperglycemia and hyperinsulinemia in pregnancies of STZ-treated monkeys (1 52 ).
An appropriate model of the diabetic pregnancy could provide answers to the following questions. 
